ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 232 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2022. The put-call ratio across all filers is 0.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,229,918 | -26.7% | 26,662 | -36.3% | 0.06% | -10.6% |
| Q1 2023 | $1,677,944 | +52.9% | 41,844 | +76.7% | 0.07% | +65.0% |
| Q4 2022 | $1,097,187 | -78.5% | 23,682 | -80.8% | 0.04% | -77.7% |
| Q3 2022 | $5,101,000 | +471.2% | 123,189 | +902.0% | 0.18% | +426.5% |
| Q1 2022 | $893,000 | -15.7% | 12,294 | -2.4% | 0.03% | -17.1% |
| Q4 2021 | $1,059,000 | -90.8% | 12,590 | -90.2% | 0.04% | -90.3% |
| Q3 2021 | $11,553,000 | -22.3% | 128,100 | -17.8% | 0.42% | +24.4% |
| Q2 2021 | $14,862,000 | +1259.7% | 155,864 | +1523.6% | 0.34% | +900.0% |
| Q1 2021 | $1,093,000 | – | 9,600 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |